These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36096240)

  • 1. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
    Luo Y; Li H
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of class I HDAC modulators: Inhibitors and degraders.
    Huang Z; Zeng L; Cheng B; Li D
    Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
    Mody D; Bouckaert J; Savvides SN; Gupta V
    Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
    Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
    Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
    Weïwer M; Lewis MC; Wagner FF; Holson EB
    Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity-Guided Design of HDAC11-Specific Inhibitors.
    Son SI; Cao J; Zhu CL; Miller SP; Lin H
    ACS Chem Biol; 2019 Jul; 14(7):1393-1397. PubMed ID: 31264832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.
    Montero A; Beierle JM; Olsen CA; Ghadiri MR
    J Am Chem Soc; 2009 Mar; 131(8):3033-41. PubMed ID: 19239270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor based prodrugs.
    Fan W; Zhang L; Jiang Q; Song W; Yan F; Zhang L
    Eur J Med Chem; 2020 Oct; 203():112628. PubMed ID: 32679451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
    Krishna S; Kumar V; Siddiqi MI
    Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).
    Zhan P; Wang X; Liu X; Suzuki T
    Recent Pat Anticancer Drug Discov; 2017; 12(1):16-34. PubMed ID: 27804867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.